MEK inhibitors can be considered as an alternative treatment modality for children with multiple lesions or have underlying mutations in BRAF and NF1 as they can avoid the paradoxical MAPK pathway activation observed when low-grade gliomas with aberrant BRAF-KIAA1549 mutations are treated with BRAF inhibitors (75). Here, BRAF is linked to central nervous system cancer.